Homatropine HBr 5% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Cycloplegic refraction
1 or 2 drops of 5% topically; may be repeated in 5 to 10 minutes if necessary. Heavily pigmented irides may require larger doses.
Uveitis and other inflammatory conditions of the uveal tract
1 or 2 drops of 5% topically up to every 3 to 4 hours.
Contraindications
- Primary glaucoma or a tendency toward glaucoma, such as a narrow anterior chamber angle
- Hypersensitivity to any component
Ophthalmic solution, 5%, 5 mL plastic bottle
Anticholinergic; blocks the response of the iris sphincter and the accommodative muscle of the ciliary body to cholinergic stimulation, producing mydriasis and paralysis of accommodation. The label characterizes the resulting mydriasis and cycloplegia as moderately long-acting.
Warnings & Precautions
- Not for injection: For topical use only.
- Fixed dilated pupil: In keratoconus, homatropine may produce a fixed dilated pupil; risk-benefit should be considered.
- Increased susceptibility: Down's syndrome, children with brain damage, and the elderly; risk-benefit should be considered. In infants and small children, use with extreme caution.
- Homatropine poisoning: Excessive use in pediatric patients, or in certain individuals with a history of susceptibility to belladonna alkaloids, may produce systemic symptoms of homatropine poisoning.
- Excessive systemic absorption: Compress the lacrimal sac by digital pressure for two to three minutes after instillation.
- Angle closure glaucoma: To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made.
- Confusional state: Excessive topical use can potentially lead to a confusional state characterized by delirium, agitation, and rarely coma, more apt to occur in the pediatric and geriatric age groups; the specific antidote is injectable physostigmine salicylate.
- Amblyopia: Homatropine should not be used during the first three months of life due to a possible association between the cycloplegia produced and the development of amblyopia.
Common Side Effects
Transient symptoms of stinging and burning may occur. Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudates, and an eczematoid dermatitis. Thirst or dryness of mouth, eye irritation not present before therapy, or increased sensitivity of eyes to light may occur.
Pregnancy: Category C. Animal reproduction studies have not been conducted; give only if clearly needed.
Lactation: Excretion in human milk unknown; use caution.
Should not be used during the first three months of life due to a possible association between the cycloplegia produced and the development of amblyopia. Safety and effectiveness in pediatric patients have not been established.